Atopic Dermatitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for atopic dermatitis. 303 active patents protecting 16 drugs from 8+ originators. First major cliff: 2027. Daily refresh.

16
Approved drugs
303
Active US patents
65/100
Avg vulnerability
$5.7B
Annual revenue covered

Originators in Atopic Dermatitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Merck & Co. 42 patents Mayne Pharma 38 patents Generic (originally Schering) 33 patents Astellas Pharma 30 patents Eli Lilly 17 patents Fougera Pharms 8 patents Anacor Pharms Inc 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating atopic dermatitis. Each bar = one year. Y-axis scaled to peak year (47 patents).

3
26
14
27
43
28
15
29
18
30
47
31
17
32
4
33
31
34
16
35
12
36
3
37
3
38
25
39
38
40
12
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Benzamycin
BENZOYL PEROXIDE
 Mayne Pharma 38 70 — 2028-02-03
Prograf
TACROLIMUS
 Astellas Pharma 30 70 $1.6B 2028-05-30
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Diprolene
BETAMETHASONE DIPROPIONATE
 Merck & Co. 20 62 — 2027-09-27
Olumiant
baricitinib
 Eli Lilly 17 62 $1.2B 2029-03-10
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Eucrisa
Crisaborole
 Anacor Pharms Inc 8 66 — 2027-02-16
Temovate
CLOBETASOL PROPIONATE
 Fougera Pharms 8 50 — 2028-11-05
Derma-Smoothe/Fs
FLUOCINOLONE ACETONIDE
 Eurofarma 4 72 — 2027-08-12
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03
Moizerto
DIFAMILAST
 OTSUKA PHARMACEUTICAL Co., Ltd 2 53 — 2028-03-01
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13
Corectim
DELGOCITINIB
 Japan Tobacco 1 81 — 2031-09-19
Topicort
DESOXIMETASONE
 Taro 1 83 — 2028-09-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE46792 Moizerto method of use 88 2028-03-01
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
9849027 Derma-Smoothe/Fs method of use 88 2028-11-07
7998108 Derma-Smoothe/Fs method of use 83 2028-01-12
9868103 Benzamycin method of use 83 2028-08-08
12070629 Benzamycin method of use 81 2030-12-30
12083270 Cutivate method of use 81 2031-04-04
8609647 Corectim method of use 81 2031-09-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
8158616 Olumiant composition of matter 4 2032-05-31
8158616 Olumiant composition of matter 4 2032-05-31
8039451 Eucrisa composition of matter 10 2029-06-29
8158616 Olumiant composition of matter 12 2032-05-31
10588893 Moizerto composition of matter 17 2036-12-31
10537585 Decadron formulation 25 2037-12-18
9855334 Temovate formulation 25 2035-03-11
10159683 Decadron formulation 25 2034-05-23
10406332 Elocon formulation 25 2034-03-13

Related